top border
top border
Featured Programs
PD-L1 Expression as a Biomarker in RCC
The panelists, Nizar M. Tannir, MD, FACP; Carlos H. Barrios, MD; Susanne Osanto, MD, PhD; Daniel Heng, MD, MPH, FRCPC; and Paul Nathan, MBBS, PhD, FRCP, address PD-L1 expression as a potential biomarker for selecting renal cell carcinoma (RCC) treatment. View Now

In this segment, Dean F. Bajorin, MD, and Evan Y. Yu, MD, discuss atezolizumab in muscle-invasive bladder cancer. View Now

 

Featured Video

Immunotherapy in the Treatment of Follicular Lymphoma

Immunotherapy in the Treatment of Follicular Lymphoma
Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.View now

Gina Columbus

Gina Columbus highlights the latest news in oncology in this week's OncLive News Network.

Publication Bottom Border
Border Publication
x